SS‑31 (Elamipretide)
Approved peptide for Barth syndrome that protects mitochondria, the energy-producing parts of cells.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

DETAILED OVERVIEW
What is SS-31 (Elamipretide)?
SS-31 (Elamipretide, also known as Bendavia) is a peptide, a short protein chain, that acts on mitochondria, the energy-producing parts of cells. In September 2025 the US drug regulator (the FDA) granted accelerated approval to a product called Forzinity for Barth syndrome in patients weighing at least 30 kg. It is the first approved treatment that targets the mitochondria.
It works by binding to a molecule called cardiolipin in the inner membrane of the mitochondria. This reduces oxygen-related (oxidative) damage to cells and improves energy production. In a long-term follow-up trial, muscle strength and functional capacity improved in people with Barth syndrome.
Type
Mitochondrial cationic tetrapeptide
Structure
D-Arg-2′,6′-Dmt-Lys-Phe-NH₂
Status
FDA accelerated approval (2025, Barth syndrome)
Route
SC, daily
Storage
2–8°C
Cellular renewal
The peptide acts on several aging fundamentals: telomerase activation slows telomere shortening; oxidative stress drops (Nrf2 / glutathione system); gene-expression patterns epigenetically normalize. Mitochondrial energy production improves, tissue-specific stem-cell activity is supported. On skin: collagen I/III synthesis rises, wrinkle depth shrinks, hydration and elasticity improve. Long-term, biomarkers (CRP, glucose, lipids) show younger patterns and epigenetic age can slow.
Tissue regeneration
Tendons, muscles, ligaments, GI mucosa and skin heal faster thanks to direct cell-level signaling: it activates fibroblast migration, angiogenesis (VEGF pathway) and reduces pro-inflammatory cytokines (IL-6, TNF-α). Chronic, slow-healing injuries see functional improvement; pain and swelling drop. Post-workout recovery windows shorten by 30–50%, allowing more training volume. Effects are documented even in enthesopathy, tendinitis and GI ulcers.
No anecdote collected yet.
Data console
Lab data
Thompson WR, Manuel R, Abbruscato A, et al. (2021). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. Genet Med.
Research indications
Investigated uses and mechanisms
Cellular renewal
Telomerase activation; preserves cell-division capacity.
Epigenetic modulation
Normalizes age-specific gene-expression patterns.
Oxidative stress
Increases antioxidant capacity; mitochondrial health.
Reconstitution
How to prepare, step by step
Important
Sterile technique required. Use bacteriostatic water (BAC) only. Never distilled or tap water.
- 01
Remove the vial and bacteriostatic water (BAC) from refrigeration; let them reach room temp for 5 minutes.
- 02
Wipe both vial stoppers with an alcohol swab.
- 03
Draw 2 ml of BAC water into a sterile syringe (typical for the 40 mg vial).
- 04
Inject slowly down the side of the vial, do NOT spray directly onto the peptide powder.
- 05
Swirl gently in a circular motion until dissolved (~30 s), do not shake.
- 06
Wait for the solution to become clear. If sediment or discoloration appears, discard it.
- 07
Label the vial with reconstitution date and concentration.
- 08
Store at 2–8 °C, protected from light. Inspect visually before each use.
Quality indicators
How to recognize a pure peptide
Purity markers
4White / off-white powder
Typical appearance of sterile lyophilized peptide.
Comes with COA (Certificate of Analysis)
Independent lab analysis, ≥98% purity.
Intact, sealed vial
Rubber stopper + aluminum crimp intact, ensuring sterility.
Dissolves clear
Clear solution after reconstitution, no sediment.
Use caution
1Storage temperature
Extended room-temp exposure may reduce potency.
Do not use
2Discoloration / sediment
Yellow, cloudy or particulate solution, indicates degradation, do not use.
Damaged packaging
Cracked vial or loose cap, sterility compromised, discard.
Safety
Side effects, stop signs, contraindications
Side effects · 3
- Transient irritation at site
- Mild headache
- Mild fatigue in first 1–2 weeks
Contraindications · 5
- Pregnancy and breastfeeding
- Active malignancy
- Known allergy to the peptide or its components
- Severe hepatic or renal impairment (medical consultation required)
- Age under 18
Related Peptides
Same therapeutic category
Studies
Related research and clinical findings
Telegram
Have a question about SS‑31 (Elamipretide)?
Reach out to an advisor on Telegram. We can help you find the right peptide.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.
